دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review
André G.GouveiaabDominic C.W.ChancPeter J.HoskindeGustavo N.MartabfFabioTrippagErnestoMaranzanogEdwardChowhMauricio F.Silvabij
doi : 10.1016/j.radonc.2021.07.022
Volume 163, October 2021, Pages 55-67
In patients with bone metastases (BM), radiotherapy (RT) is used to alleviate symptoms, reduce the risk of fracture, and improve quality of life (QoL). However, with the emergence of concepts like oligometastases, minimal invasive surgery, ablative therapies such as stereotactic ablative RT (SABR), radiosurgery (SRS), thermal ablation, and new systemic anticancer therapies, there have been a paradigm shift in the multidisciplinary approach to BM with the aim of preserving mobility and function survival.
Evolution of materials for implants in metastatic spine disease till date – Have we found an ideal material?
NareshKumaraKeith GerardLopezaSridharanAlathur RamakrishnanaJames Thomas Patrick DecourcyHallinanbJerry Ying HsiFuhcNaveenPanditaaSirishaMadhuaAravindKumardLorin M.BennekereBalamurugan A.Vellayappanf
doi : 10.1016/j.radonc.2021.08.007
Volume 163, October 2021, Pages 93-104
“Metastatic Spine Disease” (MSD) often requires surgical intervention and instrumentation with spinal implants. Ti6Al4V is widely used in metastatic spine tumor surgery (MSTS) and is the current implant material of choice due to improved biocompatibility, mechanical properties, and compatibility with imaging modalities compared to stainless steel. However, it is still not the ideal implant material due to the following issues. Ti6Al4V implants cause stress-shielding as their Young’s modulus (110 gigapascal [GPa]) is higher than cortical bone (17–21 GPa). Ti6Al4V also generates artifacts on CT and MRI, which interfere with the process of postoperative radiotherapy (RT), including treatment planning and delivery. Similarly, charged particle therapy is hindered in the presence of Ti6Al4V. In addition, artifacts on CT and MRI may result in delayed recognition of tumor recurrence and postoperative complications. In comparison, polyether-ether-ketone (PEEK) is a promising alternative. PEEK has a low Young’s modulus (3.6 GPa), which results in optimal load-sharing and produces minimal artifacts on imaging with less hinderance on postoperative RT. However, PEEK is bioinert and unable to provide sufficient stability in the immediate postoperative period. This issue may possibly be mitigated by combining PEEK with other materials to form composites or through surface modification, although further research is required in these areas. With the increasing incidence of MSD, it is an opportune time for the development of spinal implants that possess all the ideal material properties for use in MSTS. Our review will explore whether there is a current ideal implant material, available alternatives and whether these require further investigation.
Does the uncertainty in relative biological effectiveness affect patient treatment in proton therapy?
Brita S.SørensenabJörgPawelkecdJuliaBauerfkNeil G.BurnetgAlexandruDasuhiMortenHøyeraChristian P.KargerjkMechthildKrausecdelmMarcoSchwarznTracy S.A.UnderwoodoDirkWagenaarpGillian A.WhitfieldgqArminLührr
doi : 10.1016/j.radonc.2021.08.016
Volume 163, October 2021, Pages 177-184
Clinical treatment with protons uses the concept of relative biological effectiveness (RBE) to convert the absorbed dose into an RBE-weighted dose that equals the dose for radiotherapy with photons causing the same biological effect. Currently, in proton therapy a constant RBE of 1.1 is generically used. However, empirical data indicate that the RBE is not constant, but increases at the distal edge of the proton beam. This increase in RBE is of concern, as the clinical impact is still unresolved, and clinical studies demonstrating a clinical effect of an increased RBE are emerging.
In vivo assessment of the safety of standard fractionation Temporally Feathered Radiation Therapy (TFRT) for head and neck squamous cell carcinoma: An R-IDEAL Stage 1/2a first-in-humans/feasibility demonstration of new technology implementation
ShireenParsaiaRichard Lei J.QiubPengQicGeoffreySedordClifton D.FullereEricMurraycDavidMajkszakcNicoleDoriocShlomoKoyfmancNeilWoodycNikhilJoshifJacob G.Scottc
doi : 10.1016/j.radonc.2021.07.023
Volume 163, October 2021, Pages 39-45
Prior in silico simulations of studies of Temporally Feathered Radiation Therapy (TFRT) have demonstrated potential reduction in normal tissue toxicity. This R-IDEAL Stage 1/2A study seeks to demonstrate the first-in-human implementation of TFRT in treating patients with head and neck squamous cell carcinoma (HNSCC).
Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial
EleniGkikaabc1TanjaSchimek-Jaschab1StephanieKrempdStefanLenzeMarcusStockingerfAndreaSchaefer-SchulergMichaelMixchAndreasKüstersiMarcoToschjkThomasHehrlSusanne MartinaEschmannmYves-PierreBultelnPeterHassoJochenFleckensteindAlexander HenryThiemepKarinDieckmannqMatthiasMiedererrGabrieleHollsHans ChristianRischkeacgSonjaAdebahrabJochemKönigtHaraldBindereAnca-LigiaGrosuabcUrsulaNestleabch
doi : 10.1016/j.radonc.2021.07.017
Volume 163, October 2021, Pages 32-38
The success of intensification and personalisation of the curative treatment of non-small cell lung cancer (NSCLC) is strongly associated with the precision in radiotherapy. Here, we evaluate the impact of radiotherapy protocol adherence in a prospective multicentre trial.
A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma
GuangrongYangab1DanFenga1FengLiaBangyuLuoaJianboZhuaQiaoYangcLinpengZhengaQiangDongdMingjingChenaZihanXuaLingchenLiaPingChenaJianguoSuna
doi : 10.1016/j.radonc.2021.07.024
Volume 163, October 2021, Pages 76-82
This randomized controlled phase II study investigated the efficacy, safety and underlying mechanism of maxillofacial and oral massage (MOM) in nasopharyngeal carcinoma (NPC) patients receiving intensity-modulated radiotherapy.
Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India
GovindarajGanesanaSasipriyaPonniahaVivekSundarambPraveen KumarMarimuthuaVenkatramanPitchaikannuaManigandanChandrasekaranaJanakiramanThangarasucGunasekaranKannupaiyanaPrabhuRamamoorthyaBrindhaThangarajaRaguramShree Vaishnavia
doi : 10.1016/j.radonc.2021.08.001
Volume 163, October 2021, Pages 83-90
The main cause of death in COVID-19 pneumonia is acute respiratory distress syndrome which is preceded by massive cytokine release. Low-dose radiation therapy (LDRT) has anti-inflammatory and immunomodulatory effects that can interfere with the inflammatory cascade, reducing the severity of associated cytokine release.
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trials
Rachel M.GlicksmanaStanley K.LiuabPatrickCheungabDannyVespriniabWilliamChuabHans T.ChungabGerardMortonabAndreaDeabreucMelanieDavidsonabAnanthRaviabHima BinduMusunurudJoelleHeloubeLingHobLiyingZhangcAndrewLoblawabf
doi : 10.1016/j.radonc.2021.08.017
Volume 163, October 2021, Pages 159-164
The role of elective nodal irradiation (ENI) in localized prostate cancer (PCa) is controversial. With increasing use of SBRT to the prostate, data is needed regarding the safety and efficacy of ENI using ultra-hypofractionated radiation (UHRT).
Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial
TobiasForsterabcAdrianeHommertgenabcMatthias FelixHäfnerabcNathalieAriansabcLailaKönigabcSemi BenHarrabiabcIngmarSchlamppabcClaraKöhleraEvaMeixnerabcVanessaHeinrichdNicolaWeidnerdJohannesHüsingeChristofSohnfJörgHeilfMichaelGolattafHolgerHofgDavidKrugabchJürgenDebusabchijJulianeHörner-Rieberabchk
doi : 10.1016/j.radonc.2021.08.019
Volume 163, October 2021, Pages 165-176
We recently published 2-year results of the prospective, randomized IMRT-MC2 trial, showing non-inferior local control and cosmesis in breast cancer patients after conventionally fractionated intensity-modulated radiotherapy with simultaneously integrated boost (IMRT-SIB), compared to 3D-conformal radiotherapy with sequential boost (3D-CRT-seqB). Here, we report on 2-year quality of life results.
Fiducial marker motion relative to the tumor bed has a significant impact on PTV margins in partial breast irradiation
NienkeHoekstraaStevenHabrakenaAnnemarieSwaak - KragtenaJean-PhilippePignolbMischaHoogemana
doi : 10.1016/j.radonc.2021.07.020
Volume 163, October 2021, Pages 1-6
With the introduction of accelerated partial breast irradiation (APBI) and the trend of reducing the number of fractions, the geometric accuracy of treatment delivery becomes critical. APBI patient setup is often based on fiducials, as the seroma is frequently not visible on pretreatment imaging. We assessed the motion of fiducials relative to the tumor bed between planning CT and treatment, and calculated margins to compensate for this motion.
Validation of separate multi-atlases for auto segmentation of cardiac substructures in CT-scans acquired in deep inspiration breath hold and free breathing
Daan S.SpooraNanna M.SijtsemaaVeerle A.B.van den BogaardaArjenvan der SchaafaCharlotte L.BrouweraBastiaan D.P.TaaRozemarijnVliegenthartbRoel G.J.KierkelsaJohannes A.LangendijkaJohn H.MaduroaFemke B.J.PetersaAnne P.G.Crijnsa
doi : 10.1016/j.radonc.2021.07.025
Volume 163, October 2021, Pages 46-54
Developing NTCP-models for cardiac complications after breast cancer (BC) radiotherapy requires cardiac dose-volume parameters for many patients. These can be obtained by using multi-atlas based automatic segmentation (MABAS) of cardiac structures in planning CT scans. We investigated the relevance of separate multi-atlases for deep inspiration breath hold (DIBH) and free breathing (FB) CT scans.
Implant risk failure in patients undergoing postmastectomy 3-week hypofractionated radiotherapy after immediate reconstruction
Damaris PatriciaRojasaMaria CristinaLeonardia1SamueleFrassonibAnnaMorraaMarianna AlessandraGerardiaElianaLa RoccaafFedericaCattanicRosaLuraschicCristianaFodoraMattiaZaffaroniaMarioRietjensdFrancescaDe LorenzidPaoloVeronesiefViviana EnricaGalimbertieMattiaIntraeVincenzoBagnardibRobertoOrecchiagSamanthaDicuonzoa2Barbara AlicjaJereczek-Fossaaf
doi : 10.1016/j.radonc.2021.08.006
Volume 163, October 2021, Pages 105-113
To evaluate reconstruction failure (RF) rate in patients receiving implant-based immediate breast reconstruction (IBR) and hypofractionated (HF) postmastectomy radiation therapy (PMRT).
Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy
Maria CristinaLeonardiaCamillaArrobbioab1SaraGandinicStefaniaVolpeabFrancescaColomboabElianaLa RoccaabVivianaGalimbertidSabrinaKahler-Ribeiro-FontanadCristianaFodoraSamanthaDicuonzoaDamaris PatriciaRojasaMaria AlessiaZerellaaAnnaMorraaEmiliaMontagnaeMarcoColleonieGiovanniMazzarolfLaura LaviniaTravainigMattiaZaffaroniaPaoloVeronesibdRobertoOrecchiahBarbara AlicjaJereczek-Fossaab
doi : 10.1016/j.radonc.2021.08.013
Volume 163, October 2021, Pages 128-135
To assess the rate of positive non-sentinel lymph nodes (non-SLNs) after neoadjuvant systemic therapy (NAST) in breast cancer (BC) following positive sentinel lymph node biopsy (SLNB).
Study of relationship between dose, LET and the risk of brain necrosis after proton therapy for skull base tumors
MagdalenaGarbaczaFrancesco GiuseppeCordonibcMarcoDurantedeJanGajewskiaKamilKisielewiczfNilsKrahglRenataKope?aPawe?OlkoaVincenzoPaterahiIlariaRinaldijMarzenaRydygieraAngeloSchiaviiEmanueleScifonicTomaszSkórafFrancescoTommasinockAntoniRucinskia
doi : 10.1016/j.radonc.2021.08.015
Volume 163, October 2021, Pages 143-149
We investigated the relationship between RBE-weighted dose (DRBE) calculated with constant (cRBE) and variable RBE (vRBE), dose-averaged linear energy transfer (LETd) and the risk of radiographic changes in skull base patients treated with protons.
Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy?
TingLiuab1Li-TingLiuab1Jie-YiLinab1Bo-WenShenc1Shan-ShanGuoabSai-LanLiuabXue-SongSunabYu-JingLiangabMei-JuanLuoabXiao-YunLiabQiu-YanChenabLin-QuanTangabHai-QiangMaiab
doi : 10.1016/j.radonc.2021.08.010
Volume 163, October 2021, Pages 185-191
Unsatisfactory tumor response to induction chemotherapy (IC) is an adverse prognostic factor of locoregionally advanced nasopharyngeal carcinoma (LANPC). A re-induction strategy which applies additional cycles of an alternative IC regimen prior to radiotherapy (RT) has been adopted.
Cranial neuropathies in advanced nasopharyngeal carcinoma: Neurological recovery after modern radiotherapy and systemic chemotherapy
James C.H.ChowaAnnaLeebKelvin K.H.BaoaK.M.CheungaJeffrey C.H.ChanaAnthony H.P.TamaWinnie W.Y.SungaTherese Y.M.TsuiaElizabeth Y.H.ChukaDaniel H.S.ChungaK.H.WongaAnussaraPrayongratcChawalitLertbutsayanukulcDanitaKannarunimitcChakkapongChakkabatcSarinKitpanitc
doi : 10.1016/j.radonc.2021.08.022
Volume 163, October 2021, Pages 221-228
Cranial neuropathy is a common presenting symptom of advanced T4 nasopharyngeal carcinoma (NPC). Data on neurological outcomes after modern intensity-modulated radiotherapy (IMRT) and chemotherapy are scarce.
Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC
AhsanFarooqiaEthan B.LudmiraKyle G.MitchellbMara B.AntonoffbChadTangaPercyLeeaJoeChangaYasirElamincDaniel R.GomezdSaumil J.Gandhia
doi : 10.1016/j.radonc.2021.08.005
Volume 163, October 2021, Pages 114-118
Local consolidative therapy (LCT) for oligometastatic non-small cell lung cancer (NSCLC) is an evolving treatment paradigm. We investigated whether the biologically effective dose (BED) of consolidative radiation therapy (RT) to the primary tumor predicted for improved local control, progression-free survival (PFS), and overall survival (OS) among NSCLC patients presenting with oligometastatic disease.
Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial
Rachel M.GlicksmanaAndrewLoblawabGerardMortonabEwaSzumacherabHans T.ChungabDannyVespriniabWilliamChuabStanley K.LiuabRichardChoocAndreaDeabreudAlexandreMamedovdLiyingZhangdPatrickCheungab
doi : 10.1016/j.radonc.2021.07.018
Volume 163, October 2021, Pages 21-31
To report on long-term results of elective pelvic nodal irradiation (EPNI) and a simultaneous hypofractionated prostate boost for high-risk prostate cancer.
Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis
MaxPetersa1Astrid A.C.de LeeuwaChristel N.NomdenaKariTanderupbKathrinKirchheinercJacob C.LindegaardbChristianKirisitscChristineHaie-MederdAlinaSturdzacLarsFokdalbUmeshMahantshettyePeterHoskinfBarbaraSegedingKjerstiBruheimhBhavanaRaiiFleurHuangjRachelCooperkElzbietavan der Steen-BanasiklErikvan LimbergenmBradley R.PietersnLi TeeTanoPeter S.N.van RossumaNicoleNesvacilcRemiNoutpMaximilian P.SchmidcRichardPöttercIna M.Jürgenliemk-SchulzaEMBRACE Collaborative Group
doi : 10.1016/j.radonc.2021.08.020
Volume 163, October 2021, Pages 150-158
To assess risk factors for nodal failure (NF) after definitive (chemo)radiotherapy and image-guided brachytherapy for locally advanced cervical cancer (LACC) for patients treated in the EMBRACE I study.
Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model
Tiuri E.KroeseabJasvirJairamabJelle P.RuurdabSteven H.LincRadheMohandStellaMookaSaskiaHaitjemaeImoHoefereNadiaHaj MohammadfMaxPetersaRichardvan HillegersbergbPeter S.N.van Rossuma
doi : 10.1016/j.radonc.2021.08.009
Volume 163, October 2021, Pages 192-198
The incidence of grade 4 lymphopenia in patients treated with chemoradiotherapy (CRT) according to Chemoradiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) regimen is unclear. The primary aim was to determine the incidence of grade 4 lymphopenia during CROSS for esophageal cancer. Secondary aims were to externally validate a prediction model for grade 4 lymphopenia and compare overall survival between patients with and without grade 4 lymphopenia.
Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study
SumanShresthaabJames E.BatescQiLiudSusan A.SmithaKevin C.OeffingereEric J.ChowfAashish C.GuptaabConstance A.OwensabLouis S.ConstinegBradford S.HoppehWendy M.LeisenringfYingQiaoaRita E.WeathersaLaurence E.CourtabChelsea C.PinnixiStephen F.KryabDaniel A.MulrooneyjkGregory T.ArmstrongkYutakaYasuik1Rebecca M.Howellab1
doi : 10.1016/j.radonc.2021.08.012
Volume 163, October 2021, Pages 199-208
We previously evaluated late cardiac disease in long-term survivors in the Childhood Cancer Survivor Study (CCSS) based on heart radiation therapy (RT) doses estimated from an age-scaled phantom with a simple atlas-based heart model (HAtlas). We enhanced our phantom with a high-resolution CT-based anatomically realistic and validated age-scalable cardiac model (HHybrid). We aimed to evaluate how this update would impact our prior estimates of RT-related late cardiac disease risk in the CCSS cohort.
Proton radiotherapy for infant rhabdomyosarcoma: Rethinking young age as an adverse prognostic factor
Akash D.ParekhaDaniel J.IndelicatoaRaymond B. MailhotVegaaRonny L.RotondobChristopher G.MorrisaScottBradfieldcJulie A.Bradleya
doi : 10.1016/j.radonc.2021.05.017
Volume 163, October 2021, Pages 215-220
In infants with rhabdomyosarcoma, young age is considered an adverse prognostic factor and treatment is often attenuated to reduce side effects. Proton therapy may improve the therapeutic ratio in these patients. We report outcomes in infants with rhabdomyosarcoma treated with proton therapy.
Experimental assessment of inter-centre variation in stopping-power and range prediction in particle therapy
NilsPetersabPatrickWohlfahrtabChristina V.DahlgrencLudovicde MarzideMalteEllerbrockfFrancescoFracchiollagJeffreyFreehCarlesGomàiJoannaGórajMaria F.JensenkTomaszKajdrowiczlRanaldMackaymSilviaMolinellinIlariaRinaldioVasilisRompokospDorotaSiewertqPieternelvan der TolrXavierVermerensHåkanNyströmcAntonyLomaxqChristianRichterabtu
doi : 10.1016/j.radonc.2021.07.019
Volume 163, October 2021, Pages 7-13
Experimental assessment of inter-centre variation and absolute accuracy of stopping-power-ratio (SPR) prediction within 17 particle therapy centres of the European Particle Therapy Network.
Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy
HanboChenaFamke L.SchneidersaAnna M.E.BruynzeelaFrank J.LagerwaardaJohn R.van Sörnsen de KosteaPaulCobussenaOmarBohoudiaBerend J.SlotmanaAlexander V.LouiebSureshSenana
doi : 10.1016/j.radonc.2021.07.026
Volume 163, October 2021, Pages 14-20
Stereotactic ablative radiotherapy (SABR) can achieve good local control for metastatic adrenal lesions. Magnetic resonance (MR)-guidance with daily on-table plan adaptation can augment the delivery of SABR with greater dose certainty. The goal of this study was to quantify the potential clinical benefit MR-guided daily-adaptive adrenal SABR using the normal tissue complication probability (NTCP) framework.
Low dose cone beam CT for paediatric image-guided radiotherapy: Image quality and practical recommendations
AbigailBryce-Atkinsona1RianneDe Jongb1TomMarchantcGillianWhitfielddeMarianne C.AznarafArjanBelbMarcelvan Herka
doi : 10.1016/j.radonc.2021.07.027
Volume 163, October 2021, Pages 68-75
Cone beam CT (CBCT) is used in paediatric image-guided radiotherapy (IGRT) for patient setup and internal anatomy assessment. Adult CBCT protocols lead to excessive doses in children, increasing the risk of radiation-induced malignancies. Reducing imaging dose increases quantum noise, degrading image quality. Patient CBCTs also include ‘anatomical noise’ (e.g. motion artefacts), further degrading quality. We determine noise contributions in paediatric CBCT, recommending practical imaging protocols and thresholds above which increasing dose yields no improvement in image quality.
Accurate assessment of a Dutch practical robustness evaluation protocol in clinical PT with pencil beam scanning for neurological tumors
JesúsRojo-SantiagoabSteven J.M.HabrakenabDannyLathouwerscAlejandraMéndez RomeroadZoltánPerkócMischa S.Hoogemanab
doi : 10.1016/j.radonc.2021.07.028
Volume 163, October 2021, Pages 121-127
Scenario-based robust optimization and evaluation are commonly used in proton therapy (PT) with pencil beam scanning (PBS) to ensure adequate dose to the clinical target volume (CTV). However, a statistically accurate assessment of the clinical application of this approach is lacking. In this study, we assess target dose in a clinical cohort of neuro-oncological patients, planned according to the DUPROTON robustness evaluation consensus, using polynomial chaos expansion (PCE).
The impact of organ-at-risk contour variations on automatically generated treatment plans for NSCLC
FemkeVaassenaColienHazelaaraRichardCantersaStephaniePeetersaStevenPetitbWoutervan Elmpta
doi : 10.1016/j.radonc.2021.08.014
Volume 163, October 2021, Pages 136-142
Quality of automatic contouring is generally assessed by comparison with manual delineations, but the effect of contour differences on the resulting dose distribution remains unknown. This study evaluated dosimetric differences between treatment plans optimized using various organ-at-risk (OAR) contouring methods.
How LEM-based RBE and dose-averaged LET affected clinical outcomes of sacral chordoma patients treated with carbon ion radiotherapy
SilviaMolinelliaGiuseppeMagroaAndreaMairanibAlbinaAllajbejcAlfredoMirandolaaAgnieszkaChalaszczykaSaraImparatoaMarioCioccaaMaria RosariaFiorea1EsterOrlandia1
doi : 10.1016/j.radonc.2021.08.024
Volume 163, October 2021, Pages 209-214
To understand the role of relative biological effectiveness (RBE) and dose-averaged linear energy transfer (LETd) distributions in the treatment of sacral chordoma (SC) patients with carbon ion radiotherapy (CIRT).
The role of surface-guided radiation therapy for improving patient safety
HaniaAl-HallaqaVaniaBatistabcdMalinKügeleefEricFordgNatalieViscariellogJuergenMeyergh
doi : 10.1016/j.radonc.2021.08.008
Volume 163, October 2021, Pages 229-236
Emerging data indicates SGRT could improve safety and quality by preventing errors in its capacity as an independent system in the treatment room. The aim of this work is to investigate the utility of SGRT in the context of safety and quality. Three incident learning systems (ILS) were reviewed to categorize and quantify errors that could have been prevented with SGRT: SAFRON (International Atomic Energy Agency), UW-ILS (University of Washington) and AvIC (Skåne University Hospital). A total of 849/9737 events occurred during the pre-treatment review/verification and treatment stages. Of these, 179 (21%) events were predicted to have been preventable with SGRT. The most common preventable events were wrong isocentre (43%) and incorrect accessories (34%), which appeared at comparable rates among SAFRON and UW-ILS. The proportion of events due to wrong accessories was much smaller in the AvIC ILS, which may be attributable to the mandatory use of SGRT in Sweden. Several case scenarios are presented to demonstrate that SGRT operates as a valuable complement to other quality-improvement tools routinely used in radiotherapy. Cases are noted in which SGRT itself caused incidents. These were mostly related to workflow issues and were of low severity. Severity data indicated that events with the potential to be mitigated by SGRT were of higher severity for all categories except wrong accessories. Improved vendor integration of SGRT systems within the overall workflow could further enhance its clinical utility. SGRT is a valuable tool with the potential to increase patient safety and treatment quality in radiotherapy.
Comment on: May oxygen depletion explain the FLASH effect? A chemical track structure analysis?
PeterWardman
doi : 10.1016/j.radonc.2021.08.004
Volume 163, October 2021, Pages 91-92
Response to “Comment on: May oxygen depletion explain the FLASH effect? A chemical track structure analysis”
DariaBoscoloaEmanueleScifonibMarcoDuranteacMichaelKrämeraMartina C.Fussa
doi : 10.1016/j.radonc.2021.09.005
Volume 163, October 2021, Pages 237-239
Comment on “Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)”
Jaqueline Munaretto TimmBaiocchiaFrancineFischer-SgrottbGlaucoBaiocchic
doi : 10.1016/j.radonc.2021.07.005
Volume 163, October 2021, Pages 240-241
Response to the Comment on “Photobiomodulation therapy for the prevention of acute radiation dermatitis (RD) in head and neck cancer patients (DERMISHEAD trial)” by Baiocchi et al
JolienRobijnsaJoyLodewijckxaStefanClaesbLeenVan BeverbLucPannekoekebSandrineCensabellabLoreBusséaDoraColsonaIrisKaminskiaVictoriaBrouxaSofiePutsaSofieVanmechelenaAnTimmermanscLeenNoébPaulBulensbMiekeGoversdAnneliesMaesbdJeroenMebisae
doi : 10.1016/j.radonc.2021.07.002
Volume 163, October 2021, Pages 242-243
Corrigendum to “Commissioning and clinical implementation of an Autoencoder based Classification-Regression model for VMAT patient-specific QA in a multi-institution scenario” [Radiother. Oncol. 161 (2021) 230–240]
RuijieYanga1XueyingYangb1LeWangcd1DingjieLieYuexinGuofYingLigYuminGuanhXiangyangWuiShoupingXujShumingZhangakMaria F.ChanlLishengGengbmJingSuidn
doi : 10.1016/j.radonc.2021.08.003
Volume 163, October 2021, Pages 119-120
Corrigendum to "A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients" [Radiother Oncol 156 (2021) 127-135]?
Sophie C.J.BosmaaMarlousHoogstraatbErikvan WerkhovencMichielde MaakerdFemkevan der LeijePaula H.M.ElkhuizenaAlainFourquetfPhilipPoortmansghLiesbeth J.BoersmaiHarryBartelinkaMarc J.van de VijverjYoung Boost Trial research group
doi : 10.1016/j.radonc.2021.03.037
Volume 163, October 2021, Page 244
Corrigendum to “Local control and postponement of systemic therapy after modest dose radiotherapy in oligometastatic myxoid liposarcomas” [Radiother. Oncol. 158 (2021) 33–39]
JulesLansuaWinan J.van HoudtbKirstenvan LangeveldecPiet L.A.van den EndedWinette T.A.van der GraafeYvonneSchragebHestervan BovenfAstrid N.ScholtenaRick L.Haasag
doi : 10.1016/j.radonc.2021.05.018
Volume 163, October 2021, Page 245
Corrigendum to “Extent of paranasal sinus involvement and its prognostic value in nasopharyngeal carcinoma: Proposed modification in the current UICC/AJCC staging system” [Radiother Oncol 160 (2021) 221–227]
Xiao-YiWang12Si-YuZhu1Wei-JieWuHao-JiangLiJiaoLiXiao-FengLinLiLiLi-ZhiLiu
doi : 10.1016/j.radonc.2021.07.007
Volume 163, October 2021, Page 246
Corrigendum to: “BMI1-KLF4 axis deficiency improves responses to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer” [Radiother Oncol 149 (2020) 249–258]
Yin-ChouHsuabChi-WenLuocWei-LunHuangadChun-ChiehWueChia-LinChoufgChih-I.ChenhShu-JyuanChangiChee-YinChaieHui-ChingWangajTzu-YiChenaChien-FengLiklmMei-RenPana
doi : 10.1016/j.radonc.2021.07.013
Volume 163, October 2021, Pages 247-248
